中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎抗病毒治疗中的常见问题

焦健 王江滨

引用本文:
Citation:

丙型肝炎抗病毒治疗中的常见问题

详细信息
  • 中图分类号: R512.6

  • [1]Fried MW, Shiffman ML, Reddy R, et al.Peg-interferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347∶975-982
    [2]Fried MW.Side effects of therapy of hepatitis C and their manage-ment[J].Hepatology, 2002, 36 (5) ∶S237-244.
    [3]Zeuzem S, Diago M, Gane E, et al.Controlled study for the treat-ment of patients with chronic hepatitis C and persistently normal ALTlevels with Peginterferon alfa-2a (40Kd) (Pegasys) and Ribavirin (Copegus) [J].Hepatology, 2003, 38 (4) ∶Suppl 1.
    [4]Bressler B, Guindi M, Tomlinson G, et al.High body mass index isan independent risk facotr for nonresponse to antiviral treatment inchronic hepatitis C[J].Hepatology, 2003, 38 (3) ∶639-644.
    [5]Poynark T, Ratziu V, McHutchison J, et al.Effect of treatment withPeginterferon or interferon alfa-2b and Ribavirin on steatosis in pa-tients infected with hepatitis C[J].Hepatology, 2003, 38∶75-85.
    [6]Foster GR, Fried MW, Hadziyannis SJ, et al.Treatment of chronichepatitis C with Peginterferon alfa-2a (40kD) (Pegasys) and Riba-virin (Copegus) :patients age has a marked influence on he individualestimated probability of achieving a sustained virologicalresponse[J].Hepatology, 2003, 38 (4) ∶Suppl 1.
    [7]Davis GI, Wong JB, McHutchison JG, et al.Early virologic re-sponse to treatment with Peginterferon alfa-2b plus Ribavirin in pa-tients with chronic hepatitis C[J].Hepatology, 2003, 38 (3) ∶645-652.
    [8]Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al.Results of A-PRICOT:A randomized, partially blinded international trial evalua-ting Peginterferon 2a+Ribvirion vs.interferon+Ribvirion in thetreatment of HCV and HIV/HCV co-infection[R].Presented at the11thCongress on Retroviruses and Opportunistic Infections, SanFrancisco Feb 8-11, 2004, Abstract 112.
    [9]Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy re-duces the risk for hepatocellucar carcinoma:national surveillanceprograrn cirrhotic and non-cirrhotic patients with chronic hepatitis Cin Japan[J].Ann Intern Med, 1999, 131 (3) ∶174-181.
    [10]Forns X, Garcia-Retarillo M, Serrano T, et al.Antivirial therapyof patients with decompensated cirrhosis to prevent recurrence of hep-atitis after liver transplantation[J].J Hepatol, 2003, 39∶389-396.
  • 加载中
计量
  • 文章访问数:  1995
  • HTML全文浏览量:  35
  • PDF下载量:  957
  • 被引次数: 0
出版历程
  • 出版日期:  2007-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回